Heat shock protein 90α inhibitor, PU-H71 in combination with DHEA promoting apoptosis in triple-negative breast cancer cell line MDA-MB-231

5Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

Abstract

Due to the lack of markers (ER, PR, and HER-2/Neu) for the molecular-targeted therapies triple-negative breast cancer (TNBC) is more challenging than other subtypes of breast cancer. Moreover, the conventional chemother-apeutic agents are still the mainstay of most therapeutic protocols and eventually turn into a refractory drug-resistance, hence, more efcient therapeutic regimens are urgently required. The present study aimed to elucidate the efects of PU-H71 combined with DHEA on triple-negative breast cancer cell line MDA-MB-231 and to assess the synergy using the Chou-Talalay method. The combined therapy controlled the expression of an array of antioxidants and metabolizing enzymes, leading to the induction of oxidative stress which in turn induced apoptotic cell death. Our results indicated that the combined treatment with PU-H71 and DHEA exerts a syner-gistic anti-tumor efect on MDA-MB-231 triple-negative breast cancer cell line.

Cite

CITATION STYLE

APA

Soudan, H., Saeed, H., Eldemellawy, M., Shalaby, M., Hassan, M., Elkewedi, M., & El-Nikhely, N. (2020). Heat shock protein 90α inhibitor, PU-H71 in combination with DHEA promoting apoptosis in triple-negative breast cancer cell line MDA-MB-231. Acta Biochimica Polonica, 67(4), 561–570. https://doi.org/10.18388/ABP.2020_5418

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free